Trial Profile

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALTO 101 (Primary)
Indications Cognition disorders; Schizophrenia
Focus Proof of concept; Therapeutic Use
Sponsors Alto Neuroscience

Most Recent Events

01 Apr 2025 Planned number of patients changed from 72 to 82.
20 Jun 2024 According to an Alto Neuroscience media release, company announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ALTO-101 in development for the treatment of cognitive impairment associated with schizophrenia (CIAS). Alto expects to report top-line data from the Phase 2 study in the second half of 2025.
20 Jun 2024 Status changed from planning to recruiting, according to an Alto Neuroscience media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com